Can knowledge about heterogeneity in treatment effects help us choose wisely?

Annals of Internal Medicine

Volumn 166, Issue 2, 2017, Pages 141-142

  Davidoff, Frank ^a,b  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE OUTCOME; CLINICAL DECISION MAKING; CLINICAL OUTCOME; GENE MAPPING; GENETIC HETEROGENEITY; HUMAN; KNOWLEDGE; NOTE; PRIORITY JOURNAL; TREATMENT OUTCOME; EVIDENCE BASED MEDICINE; RISK ASSESSMENT;

CLINICAL DECISION-MAKING; EVIDENCE-BASED MEDICINE; HUMANS; KNOWLEDGE; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 85020379197     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M16-1721     Document Type: Note

References (10)

1. Casarett D. The science of choosing wisely - overcoming the therapeutic illusion. N Engl J Med. 2016;374:1203-5. [PMID: 27028909] doi:10.1056/NEJMp1516803
2. Bothwell LE, Greene JA, Podolsky SH, Jones DS. Assessing the gold standard - lessons from the history of RCTs. N Engl J Med. 2016; 374:2175-81. [PMID: 27248626] doi:10.1056/NEJMms1604593
3. Dahabreh IJ, Hayward RA, Kent DM. Using group data to treat individuals: understanding heterogeneous treatment effects in the age of precision medicine and patient-centered evidence. Int J Epidemiol. 2016: [Forthcoming].
4. Kent DM, Nelson J, Dahabreh IJ, Rothwell PM, Altman DG, Hayward RA. Risk and treatment effect heterogeneity: re-analysis of individual participant data from 32 large clinical trials. Int J Epidemiol. 2016. [PMID: 27375287]
5. Schmid CH, Lau J, McIntosh MW, Cappelleri JC. An empirical study of the effect of the control rate as a predictor of treatment efficacy in meta-analysis of clinical trials. Stat Med. 1998;17:1923-42. [PMID: 9777687]
6. Rothwell PM, ed. Treating Individuals. From Randomised Trials to Personalised Medicine. New York: Elsevier; 2007.
7. Kent DM, Rothwell PM, Ioannidis JP, Altman DG, Hayward RA. Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal. Trials. 2010;11:85. [PMID: 20704705] doi:10.1186/1745-6215-11-85
8. Hayward RA, Kent DM, Vijan S, Hofer TP. Multivariable risk prediction can greatly enhance the statistical power of clinical trial subgroup analysis. BMC Med Res Methodol. 2006;6:18. [PMID: 16613605]
9. Gagnier JJ, Moher D, Boon H, Beyene J, Bombardier C. Investigating clinical heterogeneity in systematic reviews: a methodologic review of guidance in the literature. BMC Med Res Methodol. 2012; 12:111. [PMID: 22846171] doi:10.1186/1471-2288-12-111
10. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:2889-934. [PMID: 24239923] doi:10.1016/j.jacc.2013.11.002